HOUSTON, Oct. 3, 2017 /PRNewswire/ — ImmunoMet Therapeutics, a private biotechnology company focused on utilizing cellular metabolism to develop novel anti-tumor and immuno-oncology therapies, today announced that the Company has initiated its Phase 1 clinical study for IM156, a potent oxidative phosphorylation (OXPHOS) inhibitor. This is a dose escalation study designed to evaluate the safety and tolerability of IM156 in patients with solid tumors. The primary endpoints of the study are to determine the maximum therapeutic dose and the randomized Phase 2 study dose.
“The initiation of our Phase 1 clinical study for our lead product, IM156, is a major milestone for ImmunoMet. We look forward to the opportunity of providing cancer patients with a potential new treatment for resistant tumors, which is still an area of significant unmet need in oncology,” said Benjamin R. Cowen, Chief Operating Officer of ImmunoMet.
Patients will be enrolled at Yonsei Medical Center (South Korea), a Sister Center of MD Anderson Cancer Center. This study will enroll 18-36 patients, and the secondary endpoints of the study are to determine pharmacodynamics, pharmacokinetics, and preliminary efficacy in solid tumor patients.
IM156 is an orally administered small molecule from the biguanide class, and it is a potent oxidative phosphorylation (OXPHOS) inhibitor. IM156 is particularly promising in that it has the potential to treat not only drug resistant cancers, but also cancers with molecular signatures of sensitivity to OXPHOS inhibition. Resistant tumor cells are very sensitive to OXPHOS inhibition due to transformation to mitochondrial OXPHOS from glycolysis. IM156 has shown strong in-vitro and in-vivo efficacy in certain cancers, including Glioblastoma (GBM), gastric and diffuse large B cell lymphoma (DLBCL).
About ImmunoMet Therapeutics
ImmunoMet Therapeutics, a private, biotechnology company, is dedicated to developing innovative oncology products to improve the quality of life and make a meaningful difference in the lives of cancer patients. The Company, a spinoff of HanAll, a Korean biopharma company, was founded in 2015 and is headquartered at JLABS in Houston. In addition to its lead program, IM156, ImmunoMet has an immuno-oncology program, IM188, in late stage lead optimization targeting immune suppressor cells to enhance the response of current immunotherapies. For more information about the Company, please visit www.immunomet.com.